Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$8.3b

Jazz Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Jazz Pharmaceuticals has been growing earnings at an average annual rate of 16.2%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 11.8% per year.

Key information

16.20%

Earnings growth rate

14.05%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate11.84%
Return on equity-10.92%
Net Margin-9.91%
Next Earnings Update05 Nov 2025

Recent past performance updates

Recent updates

Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating

Sep 24

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E

Jul 21
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly

Jul 03
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly

Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts

May 09
Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist?

Apr 27
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly

Feb 22
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly

With EPS Growth And More, Jazz Pharmaceuticals (NASDAQ:JAZZ) Makes An Interesting Case

Jan 12
With EPS Growth And More, Jazz Pharmaceuticals (NASDAQ:JAZZ) Makes An Interesting Case

Sentiment Still Eluding Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Dec 25
Sentiment Still Eluding Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Dec 23

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Nov 18

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19
User avatar

Xywav And Epidiolex Drive Market Penetration And Promise Robust Revenue Growth Amid Strategic Shifts And Innovation Focus

Strategic diversification and investments in R&D aim to reduce reliance on the oxybate franchise, focusing on oncology and Epidiolex for future growth.

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Revenue & Expenses Breakdown

How Jazz Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:JAZZ Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 254,087-4051,426781
31 Mar 254,0654821,578811
31 Dec 244,0695601,416854
30 Sep 243,9934631,376834
30 Jun 243,9103951,359869
31 Mar 243,8433311,361857
31 Dec 233,8344151,307824
30 Sep 233,794801,269782
30 Jun 233,763-871,378685
31 Mar 233,738-1561,397615
31 Dec 223,659-2241,399555
30 Sep 223,584-191,276532
30 Jun 223,481-521,222536
31 Mar 223,300-4501,291530
31 Dec 213,094-3301,399476
30 Sep 212,863-1611,326416
30 Jun 212,626401,170354
31 Mar 212,436518926306
31 Dec 202,364239880310
30 Sep 202,280179846316
30 Jun 202,217133818317
31 Mar 202,188280808295
31 Dec 192,162523762275
30 Sep 192,056609626259
30 Jun 191,988656662230
31 Mar 191,954486586224
31 Dec 181,891447625227
30 Sep 181,851520667234
30 Jun 181,793434578230
31 Mar 181,687447610214
31 Dec 171,619488544198
30 Sep 171,579372518175
30 Jun 171,541399505175
31 Mar 171,528408496174
31 Dec 161,488397480160
30 Sep 161,432363470148
30 Jun 161,399361462151
31 Mar 161,352335447139
31 Dec 151,325330433133
30 Sep 151,312328422130
30 Jun 151,278266411102
31 Mar 151,23522239994
31 Dec 141,1735840485

Quality Earnings: JAZZ is currently unprofitable.

Growing Profit Margin: JAZZ is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: JAZZ is unprofitable, but has reduced losses over the past 5 years at a rate of 16.2% per year.

Accelerating Growth: Unable to compare JAZZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JAZZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (37.3%).

Return on Equity

High ROE: JAZZ has a negative Return on Equity (-10.92%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 16:55
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jazz Pharmaceuticals plc is covered by 48 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Brian SkorneyBaird
null nullBaird